AP Biosciences Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	-	32.25	-
Gross Profit	-	32.25	-
Selling, General & Admin	73.11	43.13	34.82
Research & Development	365.95	336.6	262.68
Operating Expenses	439.06	379.73	297.5
Operating Income	-439.06	-347.48	-297.5
Interest Expense	-1.65	-1.2	-
Interest & Investment Income	13.52	10.03	2.58
Currency Exchange Gain (Loss)	4.26	-0.83	6.27
Other Non Operating Income (Expenses)	0.18	0.19	0.11
EBT Excluding Unusual Items	-422.75	-339.29	-288.54
Gain (Loss) on Sale of Assets	-	-0	-
Pretax Income	-422.75	-339.3	-288.54
Net Income	-422.75	-339.3	-288.54
Net Income to Common	-422.75	-339.3	-288.54
Shares Outstanding (Basic)	75	65	53
Shares Outstanding (Diluted)	75	65	53
Shares Change (YoY)	16.28%	22.98%	-
EPS (Basic)	-5.61	-5.24	-5.48
EPS (Diluted)	-5.61	-5.24	-5.48
Free Cash Flow	-363.41	-332.65	-277.1
Free Cash Flow Per Share	-4.83	-5.14	-5.26
Gross Margin	-	100.00%	-
Operating Margin	-	-1077.35%	-
Profit Margin	-	-1051.98%	-
Free Cash Flow Margin	-	-1031.37%	-
EBITDA	-433.93	-344.01	-290.07
D&A For EBITDA	5.13	3.46	7.42
EBIT	-439.06	-347.48	-297.5

Updated Aug 13, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.